ID   JAK2_HUMAN              Reviewed;        1132 AA.
AC   O60674; O14636; O75297;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 2.
DT   02-NOV-2010, entry version 118.
DE   RecName: Full=Tyrosine-protein kinase JAK2;
DE            EC=2.7.10.2;
DE   AltName: Full=Janus kinase 2;
DE            Short=JAK-2;
GN   Name=JAK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=98289582; PubMed=9618263; DOI=10.1006/bbrc.1998.8685;
RA   Saltzman A., Stone M., Franks C., Searfoss G., Munro R., Jaye M.,
RA   Ivashchenko Y.;
RT   "Cloning and characterization of human Jak-2 kinase: high mRNA
RT   expression in immune cells and muscle tissue.";
RL   Biochem. Biophys. Res. Commun. 246:627-633(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=98118198; PubMed=9446644;
RA   Dalal I., Arpaia E., Dadi H., Kulkarni S., Squire J., Roifman C.M.;
RT   "Cloning and characterization of the human homolog of mouse Jak2.";
RL   Blood 91:844-851(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION WITH ETV6.
RX   MEDLINE=97465498; PubMed=9326218;
RA   Peeters P., Raynaud S.D., Cools J., Wlodarska I., Grosgeorge J.,
RA   Philip P., Monpoux F., Van Rompaey L., Baens M., Van Den Berghe H.,
RA   Marynen P.;
RT   "Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-
RT   associated kinase JAK2 as a result of t(9;12) in a lymphoid and
RT   t(9;15;12) in a myeloid leukemia.";
RL   Blood 90:2535-2540(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   INTERACTION WITH SKB1.
RX   MEDLINE=20002682; PubMed=10531356; DOI=10.1074/jbc.274.44.31531;
RA   Pollack B.P., Kotenko S.V., He W., Izotova L.S., Barnoski B.L.,
RA   Pestka S.;
RT   "The human homologue of the yeast proteins Skb1 and Hsl7p interacts
RT   with Jak kinases and contains protein methyltransferase activity.";
RL   J. Biol. Chem. 274:31531-31542(1999).
RN   [6]
RP   INTERACTION WITH STAM2.
RC   TISSUE=Fetal brain;
RX   MEDLINE=20359291; PubMed=10899310; DOI=10.1016/S0014-5793(00)01760-9;
RA   Endo K., Takeshita T., Kasai H., Sasaki Y., Tanaka N., Asao H.,
RA   Kikuchi K., Yamada M., Chenb M., O'Shea J.J., Sugamura K.;
RT   "STAM2, a new member of the STAM family, binding to the Janus
RT   kinases.";
RL   FEBS Lett. 477:55-61(2000).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH IL23R.
RX   MEDLINE=22018152; PubMed=12023369;
RA   Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J.,
RA   Pflanz S., Zhang R., Singh K.P., Vega F., To W., Wagner J.,
RA   O'Farrell A.-M., McClanahan T.K., Zurawski S., Hannum C., Gorman D.,
RA   Rennick D.M., Kastelein R.A., de Waal Malefyt R., Moore K.W.;
RT   "A receptor for the heterodimeric cytokine IL-23 is composed of IL-
RT   12Rbeta1 and a novel cytokine receptor subunit, IL-23R.";
RL   J. Immunol. 168:5699-5708(2002).
RN   [8]
RP   CHROMOSOMAL TRANSLOCATION WITH PCM1.
RX   PubMed=15805263; DOI=10.1158/0008-5472.CAN-04-4263;
RA   Reiter A., Walz C., Watmore A., Schoch C., Blau I., Schlegelberger B.,
RA   Berger U., Telford N., Aruliah S., Yin J.A., Vanstraelen D.,
RA   Barker H.F., Taylor P.C., O'Driscoll A., Benedetti F., Rudolph C.,
RA   Kolb H.-J., Hochhaus A., Hehlmann R., Chase A., Cross N.C.P.;
RT   "The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute
RT   leukemia that fuses PCM1 to JAK2.";
RL   Cancer Res. 65:2662-2667(2005).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION WITH PCM1.
RX   PubMed=16034466; DOI=10.1038/sj.leu.2403879;
RA   Murati A., Gelsi-Boyer V., Adelaide J., Perot C., Talmant P.,
RA   Giraudier S., Lode L., Letessier A., Delaval B., Brunel V., Imbert M.,
RA   Garand R., Xerri L., Birnbaum D., Mozziconacci M.-J., Chaffanet M.;
RT   "PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid
RT   leukemia with t(8;9) translocation.";
RL   Leukemia 19:1692-1696(2005).
RN   [10]
RP   CHROMOSOMAL TRANSLOCATION WITH PCM1.
RX   PubMed=16091753; DOI=10.1038/sj.onc.1208850;
RA   Bousquet M., Quelen C., De Mas V., Duchayne E., Roquefeuil B.,
RA   Delsol G., Laurent G., Dastugue N., Brousset P.;
RT   "The t(8;9)(p22;p24) translocation in atypical chronic myeloid
RT   leukaemia yields a new PCM1-JAK2 fusion gene.";
RL   Oncogene 24:7248-7252(2005).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH PCM1.
RX   PubMed=16769584;
RA   Bacher U., Reiter A., Haferlach T., Mueller L., Schnittger S.,
RA   Kern W., Schoch C.;
RT   "A combination of cytomorphology, cytogenetic analysis, fluorescence
RT   in situ hybridization and reverse transcriptase polymerase chain
RT   reaction for establishing clonality in cases of persisting
RT   hypereosinophilia.";
RL   Haematologica 91:817-820(2006).
RN   [12]
RP   TISSUE SPECIFICITY, AND CHROMOSOMAL TRANSLOCATION WITH PCM1.
RX   PubMed=16424865; DOI=10.1038/sj.leu.2404104;
RA   Adelaide J., Perot C., Gelsi-Boyer V., Pautas C., Murati A.,
RA   Copie-Bergman C., Imbert M., Chaffanet M., Birnbaum D.,
RA   Mozziconacci M.-J.;
RT   "A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell
RT   lymphoma.";
RL   Leukemia 20:536-537(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-570, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=17389395; DOI=10.1073/pnas.0608638104;
RA   Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.;
RT   "Multiple reaction monitoring for robust quantitative proteomic
RT   analysis of cellular signaling networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19783980; DOI=10.1038/nature08448;
RA   Dawson M.A., Bannister A.J., Gottgens B., Foster S.D., Bartke T.,
RA   Green A.R., Kouzarides T.;
RT   "JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from
RT   chromatin.";
RL   Nature 461:819-822(2009).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 840-1132 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, MASS SPECTROMETRY, AND PHOSPHORYLATION AT
RP   TYR-1007 AND TYR-1008.
RX   PubMed=16174768; DOI=10.1182/blood-2005-06-2413;
RA   Lucet I.S., Fantino E., Styles M., Bamert R., Patel O.,
RA   Broughton S.E., Walter M., Burns C.J., Treutlein H., Wilks A.F.,
RA   Rossjohn J.;
RT   "The structural basis of Janus kinase 2 inhibition by a potent and
RT   specific pan-Janus kinase inhibitor.";
RL   Blood 107:176-183(2006).
RN   [16]
RP   VARIANT PV PHE-617.
RX   PubMed=15781101; DOI=10.1016/S0140-6736(05)71142-9;
RG   The cancer genome project;
RA   Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N.,
RA   Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N.,
RA   Scott M.A., Erber W.N., Green A.R.;
RT   "Acquired mutation of the tyrosine kinase JAK2 in human
RT   myeloproliferative disorders.";
RL   Lancet 365:1054-1061(2005).
RN   [17]
RP   ERRATUM.
RG   The cancer genome project;
RA   Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N.,
RA   Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N.,
RA   Scott M.A., Erber W.N., Green A.R.;
RL   Lancet 366:122-122(2005).
RN   [18]
RP   VARIANT ET PHE-617.
RX   PubMed=16325696; DOI=10.1016/S0140-6736(05)67785-9;
RG   The United Kingdom myeloproliferative disorders study group;
RG   The medical research council adult leukaemia working party;
RG   The Australasian leukaemia and lymphoma group;
RA   Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L.,
RA   Marsden J.T., Duffy A., Boyd E.M., Bench A.J., Scott M.A.,
RA   Vassiliou G.S., Milligan D.W., Smith S.R., Erber W.N., Bareford D.,
RA   Wilkins B.S., Reilly J.T., Harrison C.N., Green A.R.;
RT   "Definition of subtypes of essential thrombocythaemia and relation to
RT   polycythaemia vera based on JAK2 V617F mutation status: a prospective
RT   study.";
RL   Lancet 366:1945-1953(2005).
RN   [19]
RP   VARIANT PV PHE-617, AND CHARACTERIZATION OF VARIANT PV PHE-617.
RX   PubMed=15793561; DOI=10.1038/nature03546;
RA   James C., Ugo V., Le Couedic J.-P., Staerk J., Delhommeau F.,
RA   Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A.,
RA   Villeval J.L., Constantinescu S.N., Casadevall N., Vainchenker W.;
RT   "A unique clonal JAK2 mutation leading to constitutive signalling
RT   causes polycythaemia vera.";
RL   Nature 434:1144-1148(2005).
RN   [20]
RP   VARIANT PV PHE-617.
RX   PubMed=15858187; DOI=10.1056/NEJMoa051113;
RA   Kralovics R., Passamonti F., Buser A.S., Teo S.-S., Tiedt R.,
RA   Passweg J.R., Tichelli A., Cazzola M., Skoda R.C.;
RT   "A gain-of-function mutation of JAK2 in myeloproliferative
RT   disorders.";
RL   N. Engl. J. Med. 352:1779-1790(2005).
RN   [21]
RP   ASSOCIATION OF VARIANT PHE-617 WITH SUSCEPTIBILITY BUDD-CHIARI
RP   SYNDROME.
RX   PubMed=16707754; DOI=10.1056/NEJMcpc069006;
RA   Chung R.T., Iafrate A.J., Amrein P.C., Sahani D.V., Misdraji J.;
RT   "Case records of the Massachusetts General Hospital. Case 15-2006: a
RT   46-year-old woman with sudden onset of abdominal distention.";
RL   N. Engl. J. Med. 354:2166-2175(2006).
RN   [22]
RP   VARIANTS AML ASN-607 AND PHE-617.
RX   PubMed=16247455; DOI=10.1038/sj.onc.1209163;
RA   Lee J.W., Kim Y.G., Soung Y.H., Han K.J., Kim S.Y., Rhim H.S.,
RA   Min W.S., Nam S.W., Park W.S., Lee J.Y., Yoo N.J., Lee S.H.;
RT   "The JAK2 V617F mutation in de novo acute myelogenous leukemias.";
RL   Oncogene 25:1434-1436(2006).
RN   [23]
RP   VARIANT PV PHE-617.
RX   PubMed=16603627; DOI=10.1073/pnas.0601462103;
RA   Jamieson C.H.M., Gotlib J., Durocher J.A., Chao M.P., Mariappan M.R.,
RA   Lay M., Jones C., Zehnder J.L., Lilleberg S.L., Weissman I.L.;
RT   "The JAK2 V617F mutation occurs in hematopoietic stem cells in
RT   polycythemia vera and predisposes toward erythroid differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6224-6229(2006).
RN   [24]
RP   VARIANTS MYELOPROLIFERATIVE DISORDER WITH ERYTHROCYTOSIS
RP   537-PHE--LYS-539 DELINS LEU; 538-GLN-LEU-539 AND LEU-539.
RX   PubMed=17267906; DOI=10.1056/NEJMoa065202;
RA   Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A.,
RA   Stratton M.R., Futreal P.A., Erber W.N., McMullin M.F., Harrison C.N.,
RA   Warren A.J., Gilliland D.G., Lodish H.F., Green A.R.;
RT   "JAK2 exon 12 mutations in polycythemia vera and idiopathic
RT   erythrocytosis.";
RL   N. Engl. J. Med. 356:459-468(2007).
RN   [25]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-127; GLN-191; ARG-346; GLU-377;
RP   VAL-393 AND HIS-1063.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine kinase involved in various
CC       processes such as cell cycle progression, apoptosis, mitotic
CC       recombination, genetic instability and histone modifications. In
CC       the cytoplasm, plays a pivotal role in signal transduction via its
CC       association with cytokine receptors, which constitutes an
CC       initiating step in signaling for many members of the cytokine
CC       receptor superfamily including the receptors for growth hormone
CC       (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR),
CC       granulocyte-macrophage colony-stimulating factor (CSF2),
CC       thrombopoietin (THPO) and multiple interleukins. Following
CC       stimulation with erythropoietin (EPO) during erythropoiesis, it is
CC       autophosphorylated and activated, leading to its association with
CC       erythropoietin receptor (EPOR) and tyrosine phosphorylation of
CC       residues in the EPOR cytoplasmic domain. Also involved in
CC       promoting the localization of EPOR to the plasma membrane. Also
CC       acts downstream of some G-protein coupled receptors. Plays a role
CC       in the control of body weight (By similarity). In the nucleus,
CC       plays a key role in chromatin by specifically mediating
CC       phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific
CC       tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- ENZYME REGULATION: Regulated by autophosphorylation, can both
CC       activate or decrease activity (By similarity).
CC   -!- SUBUNIT: Interacts with EPOR, SIRPA and SH2B1 (By similarity).
CC       Interacts with IL23R, SKB1 and STAM2.
CC   -!- INTERACTION:
CC       P32927:CSF2RB; NbExp=2; IntAct=EBI-518647, EBI-1809771;
CC       P62993:GRB2; NbExp=1; IntAct=EBI-518647, EBI-401755;
CC       P16333:NCK1; NbExp=1; IntAct=EBI-518647, EBI-389883;
CC       P27986:PIK3R1; NbExp=1; IntAct=EBI-518647, EBI-79464;
CC       P19174:PLCG1; NbExp=1; IntAct=EBI-518647, EBI-79387;
CC       Q12913:PTPRJ; NbExp=1; IntAct=EBI-518647, EBI-2264500;
CC   -!- SUBCELLULAR LOCATION: Endomembrane system; Peripheral membrane
CC       protein (By similarity). Nucleus.
CC   -!- TISSUE SPECIFICITY: Expressed in blood, bone marrow and lymph
CC       node.
CC   -!- DOMAIN: Possesses 2 protein kinase domains. The second one
CC       probably contains the catalytic domain, while the presence of
CC       slight differences suggest a different role for protein kinase 1
CC       (By similarity).
CC   -!- PTM: Autophosphorylated, leading to regulate its activity. Leptin
CC       promotes phosphorylation on tyrosine residues, including
CC       phosphorylation on Tyr-813. Autophosphorylation on Tyr-119 in
CC       response to EPO down-regulates its kinase activity.
CC       Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972 in response to
CC       growth hormone (GH) are required for maximal kinase activity (By
CC       similarity).
CC   -!- DISEASE: Note=Chromosomal aberrations involving JAK2 are found in
CC       both chronic and acute forms of eosinophilic, lymphoblastic and
CC       myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links
CC       the protein kinase domain of JAK2 to the major portion of PCM1.
CC       Translocation t(9;12)(p24;p13) with ETV6.
CC   -!- DISEASE: Defects in JAK2 are a cause of susceptibility to Budd-
CC       Chiari syndrome (BCS) [MIM:600880]. It is a syndrome caused by
CC       obstruction of hepatic venous outflow involving either the hepatic
CC       veins or the terminal segment of the inferior vena cava.
CC       Obstructions are generally caused by thrombosis and lead to
CC       hepatic congestion and ischemic necrosis. Clinical manifestations
CC       observed in the majority of patients include hepatomegaly, right
CC       upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is
CC       associated with a combination of disease states including primary
CC       myeloproliferative syndromes and thrombophilia due to factor V
CC       Leiden, protein C deficiency and antithrombin III deficiency.
CC       Budd-Chiari syndrome is a rare but typical complication in
CC       patients with polycythemia vera.
CC   -!- DISEASE: Defects in JAK2 are a cause of polycythemia vera (PV)
CC       [MIM:263300]. A myeloproliferative disorder characterized by
CC       abnormal proliferation of all hematopoietic bone marrow elements,
CC       erythroid hyperplasia, an absolute increase in total blood volume,
CC       but also by myeloid leukocytosis, thrombocytosis and splenomegaly.
CC   -!- DISEASE: Defects in JAK2 gene may be a cause of essential
CC       thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated
CC       platelet levels due to sustained proliferation of megakaryocytes,
CC       and frequently lead to thrombotic and haemorrhagic complications.
CC   -!- DISEASE: Defects in JAK2 are a cause of myelofibrosis (MYELOF)
CC       [MIM:254450]. Myelofibrosis is a disorder characterized by
CC       replacement of the bone marrow by fibrous tissue, occurring in
CC       association with a myeloproliferative disorder. Clinical
CC       manifestations may include anemia, pallor, splenomegaly,
CC       hypermetabolic state, petechiae, ecchymosis, bleeding,
CC       lymphadenopathy, hepatomegaly, portal hypertension.
CC   -!- DISEASE: Defects in JAK2 are a cause of acute myelogenous leukemia
CC       (AML) [MIM:601626]. AML is a malignant disease in which
CC       hematopoietic precursors are arrested in an early stage of
CC       development.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. JAK subfamily.
CC   -!- SIMILARITY: Contains 1 FERM domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SIMILARITY: Contains 1 SH2 domain.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JAK98.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF058925; AAC23982.1; -; mRNA.
DR   EMBL; AF001362; AAC23653.1; -; mRNA.
DR   EMBL; AF005216; AAB82092.1; -; mRNA.
DR   EMBL; AL161450; CAD13329.1; -; Genomic_DNA.
DR   IPI; IPI00031016; -.
DR   PIR; JW0091; JW0091.
DR   RefSeq; NP_004963.1; -.
DR   UniGene; Hs.656213; -.
DR   PDB; 2B7A; X-ray; 2.00 A; A/B=840-1132.
DR   PDB; 2W1I; X-ray; 2.60 A; A/B=835-1132.
DR   PDB; 3E62; X-ray; 1.92 A; A=839-1131.
DR   PDB; 3E63; X-ray; 1.90 A; A=839-1131.
DR   PDB; 3E64; X-ray; 1.80 A; A=839-1131.
DR   PDB; 3FUP; X-ray; 2.40 A; A/B=840-1132.
DR   PDB; 3IO7; X-ray; 2.60 A; A=842-1132.
DR   PDB; 3IOK; X-ray; 2.10 A; A=842-1132.
DR   PDB; 3JY9; X-ray; 2.10 A; A=842-1130.
DR   PDB; 3KCK; X-ray; 2.20 A; A=842-1132.
DR   PDB; 3KRR; X-ray; 1.80 A; A=840-1132.
DR   PDB; 3LPB; X-ray; 2.00 A; A/B=840-1132.
DR   PDBsum; 2B7A; -.
DR   PDBsum; 2W1I; -.
DR   PDBsum; 3E62; -.
DR   PDBsum; 3E63; -.
DR   PDBsum; 3E64; -.
DR   PDBsum; 3FUP; -.
DR   PDBsum; 3IO7; -.
DR   PDBsum; 3IOK; -.
DR   PDBsum; 3JY9; -.
DR   PDBsum; 3KCK; -.
DR   PDBsum; 3KRR; -.
DR   PDBsum; 3LPB; -.
DR   ProteinModelPortal; O60674; -.
DR   SMR; O60674; 397-811.
DR   IntAct; O60674; 14.
DR   MINT; MINT-158048; -.
DR   STRING; O60674; -.
DR   PhosphoSite; O60674; -.
DR   PRIDE; O60674; -.
DR   Ensembl; ENST00000381652; ENSP00000371067; ENSG00000096968.
DR   GeneID; 3717; -.
DR   KEGG; hsa:3717; -.
DR   UCSC; uc003ziw.1; human.
DR   CTD; 3717; -.
DR   GeneCards; GC09P004975; -.
DR   H-InvDB; HIX0025698; -.
DR   HGNC; HGNC:6192; JAK2.
DR   HPA; CAB013089; -.
DR   MIM; 147796; gene.
DR   MIM; 187950; phenotype.
DR   MIM; 254450; phenotype.
DR   MIM; 263300; phenotype.
DR   MIM; 600880; phenotype.
DR   MIM; 601626; phenotype.
DR   Orphanet; 3318; Essential thrombocythemia.
DR   Orphanet; 824; Myelofibrosis with myeloid metaplasia.
DR   Orphanet; 729; Polycythemia vera.
DR   PharmGKB; PA29989; -.
DR   eggNOG; prNOG09794; -.
DR   HOGENOM; HBG445257; -.
DR   HOVERGEN; HBG006195; -.
DR   InParanoid; O60674; -.
DR   OMA; CHGPISM; -.
DR   OrthoDB; EOG93V2DS; -.
DR   PhylomeDB; O60674; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Pathway_Interaction_DB; endothelinpathway; Endothelins.
DR   Pathway_Interaction_DB; epopathway; EPO signaling pathway.
DR   Pathway_Interaction_DB; ifngpathway; IFN-gamma pathway.
DR   Pathway_Interaction_DB; il12_2pathway; IL12-mediated signaling events.
DR   Pathway_Interaction_DB; il23pathway; IL23-mediated signaling events.
DR   Pathway_Interaction_DB; il27pathway; IL27-mediated signaling events.
DR   Pathway_Interaction_DB; il4_2pathway; IL4-mediated signaling events.
DR   Pathway_Interaction_DB; il6_7pathway; IL6-mediated signaling events.
DR   Pathway_Interaction_DB; a4b1_paxindep_pathway; Paxillin-independent events mediated by a4b1 and a4b7.
DR   Pathway_Interaction_DB; s1p_s1p3_pathway; S1P3 pathway.
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Pathway_Interaction_DB; kitpathway; Signaling events mediated by Stem cell factor receptor (c-Kit).
DR   NextBio; 14567; -.
DR   ArrayExpress; O60674; -.
DR   Bgee; O60674; -.
DR   CleanEx; HS_JAK2; -.
DR   Genevestigator; O60674; -.
DR   GO; GO:0005856; C:cytoskeleton; IEA:InterPro.
DR   GO; GO:0012505; C:endomembrane system; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005131; F:growth hormone receptor binding; ISS:BHF-UCL.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0035401; F:histone kinase activity (H3-Y41 specific); IDA:UniProtKB.
DR   GO; GO:0004718; F:Janus kinase activity; ISS:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; IEA:EC.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0042977; P:activation of JAK2 kinase activity; ISS:UniProtKB.
DR   GO; GO:0006928; P:cellular component movement; TAS:ProtInc.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone...; ISS:UniProtKB.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphoryla...; ISS:BHF-UCL.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphoryla...; ISS:BHF-UCL.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0046677; P:response to antibiotic; IDA:MGI.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR016251; Tyr_kinase_non-rcpt_Jak/Tyk2.
DR   InterPro; IPR020693; Tyr_kinase_non-rcpt_Jak2.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:3.30.505.10; SH2; 1.
DR   PANTHER; PTHR23256:SF49; Tyr_kinase_non-rcpt_Jak2; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 2.
DR   Pfam; PF00017; SH2; 1.
DR   PIRSF; PIRSF000636; TyrPK_Jak; 1.
DR   PRINTS; PR01823; JANUSKINASE.
DR   PRINTS; PR01825; JANUSKINASE2.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 2.
DR   SUPFAM; SSF47031; FERM_3-hlx; 1.
DR   SUPFAM; SSF56112; Kinase_like; 2.
DR   PROSITE; PS00660; FERM_1; FALSE_NEG.
DR   PROSITE; PS00661; FERM_2; FALSE_NEG.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Chromatin regulator;
KW   Chromosomal rearrangement; Complete proteome; Disease mutation;
KW   Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Repeat; SH2 domain; Transferase;
KW   Tyrosine-protein kinase.
FT   CHAIN         1   1132       Tyrosine-protein kinase JAK2.
FT                                /FTId=PRO_0000088112.
FT   DOMAIN       37    380       FERM.
FT   DOMAIN      401    482       SH2; atypical.
FT   DOMAIN      545    809       Protein kinase 1.
FT   DOMAIN      849   1124       Protein kinase 2.
FT   NP_BIND     855    863       ATP (By similarity).
FT   ACT_SITE    976    976       Proton acceptor (By similarity).
FT   BINDING     882    882       ATP (By similarity).
FT   SITE        352    353       Breakpoint for translocation to form
FT                                PCM1-JAK2 fusion protein.
FT   SITE        442    443       Breakpoint for translocation to form
FT                                PCM1-JAK2 fusion protein.
FT   SITE        450    451       Breakpoint for translocation to form
FT                                PCM1-JAK2 fusion protein.
FT   SITE        504    505       Breakpoint for translocation to form
FT                                PCM1-JAK2 fusion protein.
FT   SITE        710    711       Breakpoint for translocation to form
FT                                PCM1-JAK2 fusion protein.
FT   MOD_RES     119    119       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     523    523       Phosphoserine (By similarity).
FT   MOD_RES     570    570       Phosphotyrosine.
FT   MOD_RES     813    813       Phosphotyrosine (By similarity).
FT   MOD_RES     868    868       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     966    966       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES     972    972       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1007   1007       Phosphotyrosine; by autocatalysis.
FT   MOD_RES    1008   1008       Phosphotyrosine; by autocatalysis
FT                                (Probable).
FT   VARIANT     127    127       G -> D (in dbSNP:rs56118985).
FT                                /FTId=VAR_041716.
FT   VARIANT     191    191       K -> Q (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041717.
FT   VARIANT     346    346       K -> R (in dbSNP:rs55667734).
FT                                /FTId=VAR_041718.
FT   VARIANT     377    377       A -> E (in dbSNP:rs55953208).
FT                                /FTId=VAR_041719.
FT   VARIANT     393    393       L -> V (in dbSNP:rs2230723).
FT                                /FTId=VAR_041720.
FT   VARIANT     537    539       FHK -> L (in myeloproliferative disorder
FT                                with erythrocytosis).
FT                                /FTId=VAR_032693.
FT   VARIANT     538    539       HK -> QL (in myeloproliferative disorder
FT                                with erythrocytosis).
FT                                /FTId=VAR_032694.
FT   VARIANT     539    539       K -> L (in myeloproliferative disorder
FT                                with erythrocytosis; requires 2
FT                                nucleotide substitutions).
FT                                /FTId=VAR_032695.
FT   VARIANT     584    584       D -> E (in dbSNP:rs17490221).
FT                                /FTId=VAR_043129.
FT   VARIANT     607    607       K -> N (in AML).
FT                                /FTId=VAR_032696.
FT   VARIANT     617    617       V -> F (in PV and AML; associated with
FT                                susceptibility to Budd-Chiari syndrome;
FT                                somatic mutation in a high percentage of
FT                                patients with essential thrombocythemia
FT                                or myelofibrosis; leads to constitutive
FT                                tyrosine phosphorylation activity that
FT                                promotes cytokine hypersensitivity).
FT                                /FTId=VAR_032697.
FT   VARIANT    1063   1063       R -> H (in dbSNP:rs41316003).
FT                                /FTId=VAR_041721.
FT   CONFLICT    321    321       P -> S (in Ref. 1; AAC23982).
FT   CONFLICT   1126   1126       I -> V (in Ref. 2; AAC23653).
FT   HELIX       846    848
FT   STRAND      849    858
FT   STRAND      861    868
FT   STRAND      872    874
FT   STRAND      878    886
FT   HELIX       889    903
FT   STRAND      913    917
FT   STRAND      926    930
FT   HELIX       937    943
FT   TURN        945    947
FT   HELIX       950    969
FT   HELIX       979    981
FT   STRAND      982    986
FT   STRAND      989    992
FT   HELIX      1018   1020
FT   HELIX      1023   1027
FT   HELIX      1033   1048
FT   TURN       1049   1051
FT   HELIX      1053   1055
FT   HELIX      1057   1065
FT   HELIX      1073   1083
FT   HELIX      1096   1105
FT   HELIX      1110   1112
FT   HELIX      1116   1131
SQ   SEQUENCE   1132 AA;  130674 MW;  C30669EF1A7DA80C CRC64;
     MGMACLTMTE MEGTSTSSIY QNGDISGNAN SMKQIDPVLQ VYLYHSLGKS EADYLTFPSG
     EYVAEEICIA ASKACGITPV YHNMFALMSE TERIWYPPNH VFHIDESTRH NVLYRIRFYF
     PRWYCSGSNR AYRHGISRGA EAPLLDDFVM SYLFAQWRHD FVHGWIKVPV THETQEECLG
     MAVLDMMRIA KENDQTPLAI YNSISYKTFL PKCIRAKIQD YHILTRKRIR YRFRRFIQQF
     SQCKATARNL KLKYLINLET LQSAFYTEKF EVKEPGSGPS GEEIFATIII TGNGGIQWSR
     GKHKESETLT EQDLQLYCDF PNIIDVSIKQ ANQEGSNESR VVTIHKQDGK NLEIELSSLR
     EALSFVSLID GYYRLTADAH HYLCKEVAPP AVLENIQSNC HGPISMDFAI SKLKKAGNQT
     GLYVLRCSPK DFNKYFLTFA VERENVIEYK HCLITKNENE EYNLSGTKKN FSSLKDLLNC
     YQMETVRSDN IIFQFTKCCP PKPKDKSNLL VFRTNGVSDV PTSPTLQRPT HMNQMVFHKI
     RNEDLIFNES LGQGTFTKIF KGVRREVGDY GQLHETEVLL KVLDKAHRNY SESFFEAASM
     MSKLSHKHLV LNYGVCVCGD ENILVQEFVK FGSLDTYLKK NKNCINILWK LEVAKQLAWA
     MHFLEENTLI HGNVCAKNIL LIREEDRKTG NPPFIKLSDP GISITVLPKD ILQERIPWVP
     PECIENPKNL NLATDKWSFG TTLWEICSGG DKPLSALDSQ RKLQFYEDRH QLPAPKWAEL
     ANLINNCMDY EPDFRPSFRA IIRDLNSLFT PDYELLTEND MLPNMRIGAL GFSGAFEDRD
     PTQFEERHLK FLQQLGKGNF GSVEMCRYDP LQDNTGEVVA VKKLQHSTEE HLRDFEREIE
     ILKSLQHDNI VKYKGVCYSA GRRNLKLIME YLPYGSLRDY LQKHKERIDH IKLLQYTSQI
     CKGMEYLGTK RYIHRDLATR NILVENENRV KIGDFGLTKV LPQDKEYYKV KEPGESPIFW
     YAPESLTESK FSVASDVWSF GVVLYELFTY IEKSKSPPAE FMRMIGNDKQ GQMIVFHLIE
     LLKNNGRLPR PDGCPDEIYM IMTECWNNNV NQRPSFRDLA LRVDQIRDNM AG
//
